Coherus: Biosimilar Specialist With Approval Shot For Cancer Drug (NASDAQ:CHRS)

recep-bg/E+ via Getty Images

Investment Overview

Redwood City, California based biotech Coherus BioSciences (NASDAQ:CHRS) ought to be an interesting stock to keep an eye on through 2023 and for the next several years.

Coherus has a market cap valuation

Coherus BioSciences product launches

Coherus’ product launch plan (JP Morgan Healthcare Presentation)

Coherus planned product launches

Coherus planned product launches (Coherus Presentation)

Leave a Reply

Your email address will not be published. Required fields are marked *